Novartis | NOVN - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 33.53B 4.47B 2026-03
Alcon AG USD 6.62B 171M 2026-03
Almirall EUR 713.98M 69K 2025-12
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Autolus Therapeutics Ltd USD 368.84M 67.08M 2026-03
Bayer EUR 35.3B 2.39B 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Fresenius EUR 11.03B 1.03B 2025-12
Fresenius Medical Care EUR 8.11B 209.55M 2026-03
Genmab DKK 2.88B 1.59B 2025-12
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
GRIFOLS EUR 5.25B 180M 2026-03
Hikma Pharmaceutical USD 2.64B 86M 2025-12
J&J USD 59.17B 3.55B 2026-03
Lakefront Biotherapeutics EUR 3.06B 18.72M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck EUR 14.16B 932M 2026-03
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novo Nordisk DKK 177.32B 4.86B 2026-03
Orion EUR 1.41B 66.8M 2026-03
Pfizer USD 42.82B 76M 2026-03
Philips EUR 9.78B 148M 2026-03
Recordati EUR 1.73B 50.28M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sanofi EUR 30.16B 789M 2026-03
UCB EUR 6.05B 733M 2025-12